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Abstract
Background: Apoptosis is important for normal cerebral cortical development. We previously showed that the
Fas suicide receptor was expressed within the developing cerebral cortex, and that in vitro Fas activation resulted
in caspase-dependent death. Alterations in cell-surface Fas expression may significantly influence cortical
development. Therefore, in the following studies, we sought to identify developmentally relevant cell biological
processes that regulate cell-surface Fas expression and reciprocal consequences of Fas receptor activation.
Results: Flow-cytometric analyses identified two distinct neural sub-populations that expressed Fas on their cell
surface at high (FasHi) or moderate (FasMod) levels. The anti-apoptotic protein FLIP further delineated a subset of
Fas-expressing cells with potential apoptosis-resistance. FasMod precursors were mainly in G0, while FasHi
precursors were largely apoptotic. However, birth-date analysis indicated that neuroblasts express the highest
levels of cell-surface Fas at the end of S-phase, or after their final round of mitosis, suggesting that Fas expression
is induced at cell cycle checkpoints or during interkinetic nuclear movements. FasHi expression was associated
with loss of cell-matrix adhesion and anoikis. Activation of the transcription factor p53 was associated with
induction of Fas expression, while the gonadal hormone estrogen antagonistically suppressed cell-surface Fas
expression. Estrogen also induced entry into S-phase and decreased the number of Fas-expressing neuroblasts
that were apoptotic. Concurrent exposure to estrogen and to soluble Fas-ligand (sFasL) suppressed p21/waf-1
and PCNA. In contrast, estrogen and sFasL, individually and together, induced cyclin-A expression, suggesting
activation of compensatory survival mechanisms.
Conclusions:  Embryonic cortical neuronal precursors are intrinsically heterogeneous with respect to Fas
suicide-sensitivity. Competing intrinsic (p53, cell cycle, FLIP expression), proximal (extra-cellular matrix) and
extrinsic factors (gonadal hormones) collectively regulate Fas suicide-sensitivity either during neurogenesis, or
possibly during neuronal migration, and may ultimately determine which neuroblasts successfully contribute
neurons to the differentiating cortical plate.
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Background
The developing cerebral cortex and other brain regions
undergo substantial cell suicide during the period of neu-
rogenesis and early differentiation [1-10], to generate a
mature brain. Mechanisms that control the survival or
death of neuroblasts and neurons in the developing cere-
bral cortex are likely to have profound effects on the
organization of cognition, affect and sensori-motor inte-
gration in the adult. One generally accepted mechanism
that is invoked to explain developmental apoptosis is the
competition among neurons for limited supplies of
trophic molecules within the environment (reviewed in
[11]). According to this model, a neuron's inability to find
growth factor support within its environment precedes
the initiation of apoptosis. However, the presence of cell-
surface suicide receptors, like the Fas/Apo [Apoptosis]-1/
CD95 receptor, and their trans-membrane ligands (e.g.,
FasL) in the developing brain [9] suggests that neural cells
may actively communicate apoptosis signals to each
other. In addition to competing for a limited supply of
trophic factors, developing neural progenitors and differ-
entiating neurons may engage in an active killing process
whereby 'killer cells' induce apoptosis in 'suicide-recep-
tive' cells, to limit cell number in the brain. It is therefore
important to understand the signaling mechanisms and
circumstances that regulate cell-suicide receptor expres-
sion in the developing brain.
The Fas cell-suicide receptor plays an important role in
limiting cell proliferation in the immune system by apop-
tosis [12]. Recent evidence suggests that Fas is also an
important regulator of cell death in the brain. Fas is
expressed by the developing cerebral cortex during the
peak period of apoptosis [7,9,13], and by other differenti-
ating neural cells [14-18]. Fas is also re-expressed in neu-
rological disease conditions including ischemia, multiple
sclerosis, Alzheimer's disease, and in neural tumors
[15,19-27]. We previously reported that Fas activation
leads to unscheduled DNA synthesis, the activation of NF-
κB, and caspase-dependent cell death in embryonic corti-
cal neuroblasts [9]. Neuronal cultures obtained from
developing gld (Fas-deficient) mice are less sensitive to
apoptosis signals than wild-type controls [17]. Finally,
haplo-insufficiency of the tyrosine phosphatase Pten/
MMAC1 results in the inactivation of Fas [28], resistance
to apoptosis in neural progenitors [29], and consequently,
an increased incidence of tumors of neural origin [30].
These data indicate that the Fas/Apo-1 suicide system may
determine cell number in the brain, both during develop-
ment, and following injury in the adult. However, we
know very little about the types of neural progenitors and
neuronal cells that are particularly vulnerable to Fas-
induced death. We also know little about the signaling
mechanisms in differentiating neural progenitors that
promote cell-surface expression of Fas, and consequently,
sensitivity to apoptosis.
The transcription factor p53 is important for brain devel-
opment [31]. In lung and prostate cancer cell lines, Fas
activation is dependent on the presence of functional p53
[32]. P53 induces Fas gene transcription [33], the translo-
cation of Fas from Golgi complex to cell surface [34] and
activates Fas-mediated apoptosis in un-transformed vas-
cular smooth muscle cells [34] and mammary epithelial
tumors [35]. In the adult rat hippocampus, seizure leads
to the co-localized expression of p53 and Fas in CA1 neu-
rons [36]. However, it is likely that p53 acts in concert
with a coterie of transcription factors to regulate the avail-
ability of Fas in the developing brain. For example, we
found that estrogen promotes p53 phosphorylation [37],
but uncouples p53 from its regulation of Bax, a mitochon-
drial-associated pro-apoptotic factor. Furthermore, estro-
gen receptors block the DNA binding activity of NF-kB
[38], a transcription factor downstream of members of the
TNFr/Fas family [9,39]. Thus estrogen, and consequently
estrogen receptors, may be an important regulator of Fas
expression in the developing cerebral cortex.
In the following experiments, we set out to identify cell
biological processes that predict cell-surface expression of
Fas, and to identify consequences of Fas activation. Our
experiments focused predominantly on the pool of Fas
receptors that localized to the cell surface, because this
population constitutes the bioactive proportion of Fas
receptors that contributes to apoptosis sensitivity. We
hypothesized that, in embryonic cerebral cortex, cell-sur-
face Fas expression would be associated with exit from cell
cycle, and activation of p53. We also hypothesized that
estrogen controls neurogenesis and neuron elimination,
either by regulating the Fas receptor, or by regulating spe-
cific anti-apoptotic cell cycle elements in a Fas-dependent
manner.
Our results indicate that embryonic cortical precursors are
heterogeneous with respect to cell surface Fas expression
and the co-expression of the anti-apoptotic protein FLIP
(FLICE/caspase-8 interacting protein). Cell-surface Fas
expression in embryonic cortical neurons is associated
with recent exit from cell cycle, and with loss of contact
with the extra-cellular matrix and anoikis. Fas expression
is coincidentally increased following p53 activation. In
contrast, estrogen decreases Fas expression, and following
the activation of Fas by soluble Fas-ligand (sFasL), estro-
gen suppresses expression of p21/Waf-1/Cip-1 and the
proliferating cell nuclear antigen (PCNA). Estrogen and
sFasL separately and together induce expression of cyclin
A.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/11
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Results
Expression of Fas and related proteins in embryonic 
cerebral cortical precursors
In the initial experiment, we utilized flow cytometric anal-
ysis to examine the localization of Fas to the cell surface of
freshly isolated embryonic rat (gestational day (GD)-15)
cortical neural cells by immuno-labeling for Fas in the
absence of detergent. At this developmental age, the neu-
roepithelium proliferates rapidly and is the dominant cor-
tical structure, and therefore, neuroepithelial precursors
are the most abundant component of this tissue. Further-
more, at this age, the neuroepithelium mainly consists of
neuronal (as opposed to glial) precursors (for review, see
[40]). Flow cytometric analysis of samples obtained from
GD15 rat cortex indicated that 10.69 ± 3.37% (mean ±
SEM) of cortical neuronal precursors expressed Fas on
their cell surface in vivo on embryonic day 15 (data
obtained from 6 independent samples of E15 cortex, Fig-
ure 1A). Once cortical precursors are cultured however,
immunohistochemical analysis of detergent-permeabi-
lized cultures (a measure of total Fas expression) indicates
that a majority of these differentiating cells localize Fas-
immunoreactivity within their cytoplasm and proximal
processes (Figure 1B vs. control Figure 1C and [9]). In
contrast, flow cytometric analyses of non-permeabilized
cultured embryonic cortical-derived neuronal precursors
(Figure 2) indicate that 23–28% of these cells expressed
Fas on their cell surface in vitro, representing ~2-fold
induction of cell surface Fas expression in vitro, as com-
pared to in vivo. Collectively, these data indicate that only
a fraction (~1/4th) of all Fas-expressing cells actually local-
ize Fas to the cell-surface, in vitro.
Co-localization of Fas with FADD and FLIP
The protein FADD (Fas-Associated Death Domain) is the
major intracellular death-inducing signaling complex
(DISC) adapter protein that couples Fas to intracellular
caspase pathways [41-44], while FLIP is the major proxi-
mal intracellular protein that blocks Fas/Apo-1-mediated
apoptosis [45]. Since FADD and FLIP are antagonistic ele-
ments of the DISC-complex and are important intracellu-
lar gates of Fas/Apo-1 activation, we examined the extent
to which these functionally divergent proteins co-local-
ized with Fas/Apo-1 in differentiating embryonic cortical-
(A) Flow cytometric analyses of independent samples GD15 cortex show more cells expressing Fas immuno-fluorescence in  samples #1–#4, compared to pre-immune serum control Figure 1
(A) Flow cytometric analyses of independent samples GD15 cortex show more cells expressing Fas immuno-fluorescence in 
samples #1–#4, compared to pre-immune serum control. Gate 'M' was set to exclude background fluorescence, or 98% of 
neuroblasts in the control sample (B & C) immunohistochemical analysis of cultured embryonic cortical neurons indicates Fas-
immunoreactivity is localized to the soma and proximal processes (arrow). Immunohistochemical controls (arrow, C) show 
lack of staining in neurons. (D) Graph (Mean ± SEM) of the percentage of Fas-expressing precursors that also co-localize the 
pro-apoptotic DISC adapter protein FADD, or the anti-apoptotic inhibitor FLIP.
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Identification of two unique populations of cell-surface Fas-expressing precursors(A-D) Figure 2
Identification of two unique populations of cell-surface Fas-expressing precursors (A-D). Flow cytometric analysis of the cell-
cycle distribution of cultured embryonic cortical precursors (A), based on frequency histogram analysis of propidium iodide 
(PI) incorporation into DNA in 10,000 cells from each sample, indicates that a majority of cells precursors are in G0. Precur-
sors with DNA content <G0 were identified as apoptotic, while precursors with >G0 DNA content were identified as being in 
S-G2-M. (B,C) Scatter-plots of two representative independent samples of embryonic cortical-derived neuronal precursors 
analyzed for combined cell-surface Fas immuno-fluorescence (y-axis) and PI incorporation (cell-cycle stage, x-axis). Based on 
background immuno-fluorescence patterns in the pre-immune serum controls (D), precursors were characterized as negative 
Fas-expressing (Fas-ve, expressing <2 × 100 fluorescence units [FUs]), moderate Fas-expressing (FasMod, expressing >2 × 100 and 
<102 FUs) and high cell surface Fas-expressing (FasHi, >102 FUs). These categories remained consistent across experiments. (E 
& F) Graphical representation (Mean ± SEM) of the proportion of precursors expressing high (FasHi, E) and moderate (FasMod, 
F) levels of cell-surface Fas at different stages of cell cycle and apoptosis, expressed as a percentage of control. Asterisks indi-
cate statistically significant differences in cell-stage-specific expression of cell surface Fas, p < 0.05.
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derived neuroblasts. Two- parameter FACS analysis (Fig-
ure 1D) showed that, among adherent cultures, 72.5 ±
2.1% of Fas-expressing neuroblasts also co-localized
FADD. In contrast, only 23.9 ± 3.2% Fas-expressing cells
co-localized the anti-apoptotic protein FLIP suggesting
that only a portion of Fas/Apo-1-expressing embryonic
cortical-derived neuronal precursors may be protected
from Fas-induced apoptosis.
Cell-cycle-related expression of Fas in embryonic cortical 
neuronal precursors
Using flow cytometric analyses, we identified three dis-
tinct populations of neural cells in vitro; based on differ-
ences in the intensity of cell-surface Fas expression (Figure
2). Approximately 3% of cortical cells expressed Fas on
their cell surface at a high intensity (FasHi), while 20% of
cultured neural cells expressed moderate levels of Fas on
their cell surface (FasMod). In contrast, 77% of cultured
cortical neural cells do not express Fas on their cell-surface
above background levels (Fas-ve). Cultured cortical cells
were counterstained with propidium iodide (PI) to meas-
ure cellular DNA content and to stage Fas-expressing cells
into apoptosis (defined as cells with less than G0 DNA
content), cell cycle arrest (G0/G1) or cell cycle (G2/S/M)
phases (Figure 2A,2B,2C,2D). Our results indicate that the
largest proportion of neural cells in the FasHi population
were apoptotic (Figure 2E). Few FasHi cells were in G0/G1
or S/G2/M stages of cell cycle. In contrast, within the Fas-
Mod population, the greatest percentage of Fas-expressing
cells was observed in G0/G1 (Figure 2F).
Functional determinants of Fas expression in cortical 
neuroblasts
The majority of FasHi cells were apoptotic. We therefore
examined the extent to which Fas expression was related
to specific apoptosis-sensitive cell-biological processes
including cell-matrix interactions, cell proliferation, and
the activation of cell-cycle inhibitory proteins like p53.
Fas expression is dependent on cell-matrix interactions 
and 'anoikis'
The loss of adhesion to the extracellular matrix has been
reported to induce apoptosis (a process referred to as
anoikis), by activating caspases like caspase-2 [46] that are
down-stream of suicide receptors like Fas/Apo-1. Such
cell-matrix interactions appear to be contextually relevant
to the developing brain as well, since deletion of the
Matrix Metalloproteinase (MMP)-9 gene (consequently
suppressing type-4 collagen degradation) leads to delayed
migration of granule cells, and decreased apoptosis in the
developing cerebellum [47]. Since post-mitotic neurob-
lasts migrate to their lamina-specific positions within the
cortical plate using guidance cues that are dependent on
the integrity of the extra-cellular matrix, we sought to
determine if there was a relationship between cell-adhe-
sion and Fas/Apo-1 expression. Non-adherent cells were
harvested and analyzed separately from cells that were
adherent to the culture dish. Among adherent cells (Figure
3A,3B), a majority of Fas-expressing neural cells belonged
to the FasMod group. In contrast, most FasHi neural cells
were non-adherent (Figure 3C,3D) and predominantly
apoptotic.
Since primary cultured cells of the FasHi group were pre-
dominantly non-adherent, we sought to determine if the
induction of 'anoikis' could lead to an increase in Fas/
Apo-1 expression. We therefore cultured embryonic day
15 cortical-derived neuroblasts on a collagen substrate
(rat tail collagen, UBI) and treated adherent cultures with
50 U of Collagenase-A (MMP-1, microbial metalloen-
dopeptidase, EC 3.4.24.3, Sigma) for 24 hours. Treatment
of adherent neuronal precursors with collagenase-A led to
a statistically significant, 2.5-fold increase in the number
of cells that expressed Fas/Apo-1 on their cell surface (Fig-
ure 3E). Because of this relationship between 'anoikis' and
Fas/Apo-1 expression, subsequent flow cytometric analy-
ses focused on cells that were adherent to the extracellular
matrix deposited onto the culture dish.
Cell surface Fas/Apo-1 expression is associated with cell 
cycle
We had previously observed that Fas activation was fol-
lowed by a transient increase in the uptake of 5-Bromo-2'-
deoxyuridine (BrdU, [9]) a marker of DNA replication.
Though this increase in BrdU incorporation was not
related to the induction of cell cycle, we hypothesized that
the expression of Fas itself was related to cell proliferation
and DNA synthesis. We therefore utilized three-parameter
flow cytometric analyses to examine the relationship
between cell-surface Fas expression and BrdU incorpora-
tion among neuronal precursors that were in cell cycle
arrest (G0/G1), or actively in cell cycle (G2/S/M). Cells
were first immuno-labeled for Fas, then detergent perme-
abilized and immuno-labeled for BrdU incorporation.
Using propidium iodide (PI) fluorescence intensity as a
classification parameter, cortical precursors were classified
as belonging to one of three phases, G2/S/M, G0/G1, or
apoptosis (sub-G0 DNA content). BrdU incorporation
was significantly correlated with the cell-surface
expression of Fas. In G0/G1 and S/G2/M conditions, cor-
relation coefficients (r) ranged from 0.98 to 0.99, p < 0.05
(Figure 4A,4B). These data suggest that Fas/Apo-1 is most
highly expressed in neuronal precursors that have recently
completed their final cycle (for neuroblasts in G0/G1) or
recently exited S-phase (for neuroblasts in S/G2/M). Fur-
thermore, among cells in cell cycle (S/G2/M, Figure 4A), a
discrete group of FasHi precursors (arrows) also expressed
the highest levels of BrdU incorporation. During cell
cycle, the highest levels of BrdU incorporation are
attained at the completion of chromosome replicationBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/11
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Relationship between Anoikis (apoptosis due to loss of cell adhesion) and cell surface Fas-expression Figure 3
Relationship between Anoikis (apoptosis due to loss of cell adhesion) and cell surface Fas-expression. (A,C) Sample frequency 
histograms of PI incorporation (DNA content) in adherent (A) and non-adherent (C) precursors indicates that adherent pre-
cursors are mainly in G0, while non-adherent precursors are mainly apoptotic. (B, D) Scatter-plots of combined analysis of PI 
(x-axis) and cell-surface Fas immunofluorescence (y-axis) indicates that adherent precursors largely express moderate levels of 
cell-surface Fas (FasMod, B), while non-adherent precursors also express high levels of Fas (FasHi, D). (E) Graph (Mean + SEM) 
showing that collagenase-A treatment significantly increased the number of cells expressing cell-surface Fas, relative to con-
trols. Asterisk indicates p < 0.05.
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Relationship between cell-surface Fas expression and BrdU incorporation at different stages of cell cycle or apoptosis (PI incor- poration) in adherent primary precursors Figure 4
Relationship between cell-surface Fas expression and BrdU incorporation at different stages of cell cycle or apoptosis (PI incor-
poration) in adherent primary precursors. (A,B) Representative frequency histogram of PI incorporation (A) and scatter-plot of 
combined PI incorporation and Fas immunofluorescence (B) indicates the thresholds for the separate analysis of BrdU content 
in neuroblasts at S/G2/M (pink), G0 (green), or apoptosis (red). (C-F) Representative scatter-plots of the overall positive rela-
tionship between Fas expression and BrdU incorporation (C) and separated by cell-phase, S/G2/M (D), G0 (E) and apoptosis 
(F). Arrows in S/G2/M condition (D) indicate a group of cells that exhibited the highest levels of BrdU incorporation (suggest-
ing recent completion of S-phase) and cell-surface Fas expression. Insets in figures D,E and F indicate Pearson's product 
moment correlations (obtained by averaging intensities across 6 independent samples). Asterisks indicate that the correlation 
was statistically significant with a 2-tailed test. These data indicate that the correlation between BrdU incorporation and cell-
surface Fas expression is higher during cell cycle and G0 as compared to apoptosis.
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(4N DNA content at the end of S-phase) and before the
completion of mitosis. Therefore, G2 and early mitosis
may represent periods during which some sub-popula-
tions of proliferating cortical neuroblasts are particularly
vulnerable to receptor-mediated suicide signals. Our data
therefore indicate that while Fas activation does not
induce or suppress cell cycle [9], the highest expression of
Fas is associated with progression past the S-phase of cell
cycle or recent exit from cell cycle.
Fas expression in embryonic cortical-derived precursors is 
associated with p53 activation
The transcription factor p53 induces Fas gene transcrip-
tion [33], the translocation of Fas from Golgi complex to
cell surface [34], and activates Fas-mediated apoptosis in
un-transformed vascular smooth muscle cells [34] and
mammary epithelial tumors [35]. We had previously
shown that p53 activation in cortical progenitor cells was
associated with the induction of the mitochondrial death-
associated protein Bax [37]. We therefore examined the
extent to which p53 status predicted the expression of Fas/
Apo-1 on the cell surface of cortical neuronal precursors.
We used phosphorylation of p53 at serine 392 as a marker
for p53 activation [37]. Cells were first immuno-labeled
for Fas, then detergent-permeabilized and immuno-
labeled for p(phospho)p53. The intensity of pp53 expres-
sion was statistically significantly correlated (p < 0.05, r =
0.73, Figure 5A) with the intensity of cell surface Fas
expression in primary cortical neuronal precursors. Thus,
cells that exhibit high levels of p53 phosphorylation also
express high cell-surface levels of Fas.
As a follow-up experiment, to determine whether p53
activation is required for the expression of Fas/Apo-1, we
utilized a rodent cerebral cortical cell line (CHB50), con-
ditionally immortalized with a temperature sensitive
mutation of the SV40 large T antigen (tsTA), that we had
previously developed and characterized [37]. In the +tsTA
condition (incubation at 33°C), neuroblasts proliferate
indefinitely and p53 is inactive as indicated by the
absence of phosphorylated p53 (-pp53). However, cessa-
tion of large T antigen expression (-tsTA, 39°C) is accom-
panied by p53 phosphorylation (+pp53) and the
induction of p53-dependent proteins like Bax [37].
CHB50 neuroblasts were therefore cultured under +tsTA
and -tsTA conditions. Western immunoblot analysis indi-
cated that CHB50 neuroblasts expressed very low-to-
undetectable levels of Fas in the -pp53 (+tsTA) condition.
However, following the activation of p53, [+pp53 (-tsTA)
condition], there was a statistically significant 12-fold
increase in the expression of Fas, 48 hours following acti-
vation of p53 (Figure 5B,5C).
Estrogen regulation of Fas expression is cell-cycle 
dependent
We had previously observed that estrogen prevented
apoptosis following p53 activation and decreased the
expression of the mitochondrial-associated pro-apoptotic
protein Bax in differentiating cerebral cortical neuroblasts
[37]. Furthermore, in the context of p53 activation, estro-
gen led to an increase in neuroblast proliferation. We
therefore examined the extent to which cell-surface Fas
expression was estrogen-dependent.
Flow cytometric analysis of non-synchronized GD15 cor-
tical neuronal precursors (Figure 6A) indicated that 24
hours exposure to estradiol-17β (E2) at 2 nM led to a sta-
tistically significant decrease in the total number of corti-
cal cells in G0 (Figure 6B) and a corresponding significant
increase in the number of neuroblasts in the DNA
synthesis (S)-phase (Figure 6C). At 24 hours there was not
a statistically significant change in the numbers of cells
progressing through G2/M (Figure 6D), suggesting that
estrogen-stimulated cells may have not yet completed cell
cycle. There was also a non-statistically-significant trend
towards a decrease in the total number of neuronal pre-
cursors that were apoptotic (Figure 6E). Our previous data
also showed that estrogen decreased the expression of
another member of the Fas family, the pan-neurotrophin
receptor p75NTR  [48,49]. We therefore also examined
estrogen regulation of cell-surface Fas expression at differ-
ent stages of cell cycle.
As observed earlier, in adherent embryonic cortical cul-
tures, most Fas expressing cells belong to the FasMod cate-
gory and very few FasHi-type cells can be observed (Figure
7A, control). Twenty-four hours of exposure to 2 nM E2
led to a statistically significant, 1.5-fold decrease in the
percentage of cells in G0/G1 that expressed Fas (Figure
7A:E2 and 7B). In contrast, the numbers of Fas expressing
cells in cell cycle, S/G2/M, were not altered by estrogen
exposure (Figure 7C), though estrogen led to a statistically
significant 2-fold decrease in the intensity of cell-surface
Fas expression (on a per-cell basis, Figure 7D). Addition-
ally, estrogen led to a statistically significant, 2-fold
decrease in the numbers of Fas-expressing cells that were
apoptotic, suggesting that estrogen suppresses apoptosis
in Fas-expressing cells (Figure 7E).
Since Fas expression was also associated with p53 activa-
tion, we hypothesized that estrogen would suppress Fas
expression in the context of p53 activation as well. We
therefore examined the expression of Fas in tsTA-CHB50
cortical neuroblasts cultured for 24 and 72 hours under
+pp53 (-tsTA) conditions, and treated for those durations
with either estradiol-17β (2 nM) alone or estradiol-17β
with the antagonist 4-hydroxytamoxifen (at 1 uM,
Sigma). Our previous western immunoblot analysesBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/11
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Fas expression is associated with p53 activation Figure 5
Fas expression is associated with p53 activation. (A) Sample flow cytometric scatter-plot showing a strong positive association 
between the intensity of p53 phosphorylation (pp53) and cell surface Fas expression in primary cortical precursors. Asterisk 
indicates statistical significance of Pearson's product moment correlation (inset). (B,C) Sample western blot (B) and quantita-
tive densitometric analysis of Fas expression in conditionally immortalized CHB50 cerebral cortical neuroblasts under -p53 
conditions (+tsTA/-pp53) and under +p53 conditions (-tsTA/+pp53) for 24 or 48 hours.
0
10
20
30
40
50
60
70 +tsTA/-p53                -tsTA/+p53
*
(+tsTA) (-tsTA) oo    33 C  39 C Mkr Mkr
   24hrs 48hrs 66 KDa
45
31
r=0.73*
Fas/Apo-1 intensity
p
p
5
3
i
n
t
e
n
s
i
t
y
A
B
C
F
a
s
/
A
p
o
-
1
E
x
p
r
e
s
s
i
o
n
(
r
e
l
a
t
i
v
e
O
D
+
S
E
M
)
o
33 C
o
39 C 24hrs
o
39 C 48hrsBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/11
Page 10 of 21
(page number not for citation purposes)
indicated that in control CHB50 cortical cultures, Fas
expression was statistically significantly induced 72 hours
following p53 activation (Figure 5B,5C). In the context of
p53 activation, estrogen led to a significant decrease in the
expression of Fas at 72 hours but not at 24 hours (Figure
8). Surprisingly (see discussion), concurrent exposure to
the estrogenic antagonist 4-hydroxytamoxifen did not
prevent the estrogen-induced reduction in Fas.
Estrogen and Fas regulation of the cell cycle-associated 
proteins
Flow cytometric analysis of primary cortical cultures indi-
cated that estrogen led to an increase in the number of
cells in S-phase (Figure 6A,6C), consistent with our previ-
ously published observations that estrogen promotes neu-
rogenesis in cortical neuroblasts [37]. Furthermore,
estrogen prevented apoptosis in cortical neuroblasts. We
therefore hypothesized that in the context of Fas activa-
tion, estrogen would alter the expression of specific cell-
cycle related proteins such as Cyclin-A [50], the Proliferat-
ing Cell Nuclear Antigen (PCNA, [51,52]) and p21/waf-1
[53], that also serve anti-apoptotic and DNA repair
functions in addition to their roles in cell cycle. For exam-
ple, PCNA and p21/Waf-1 bind to each other to prevent
apoptosis induction [51], and to promote repair of dou-
ble strand breaks in DNA, a characteristic of apoptosis. We
therefore examined if Fas activation and estrogen could
interact to regulate the expression of cyclin A, PCNA and
p21/waf-1 and compared the expression of these anti-
apoptotic cell cycle proteins with other cell-cycle proteins.
Dissociated embryonic cortical cells were exposed to solu-
ble Fas ligand (sFasL, 5 ng/ml, Alexius Corp) or estradiol-
17β (2 nM) either alone or concurrently, for 12 hours.
Western immunoblot analysis indicated that neither
estrogen nor FasL alone led to a change in the expression
of PCNA. However, concurrent exposure to both estrogen
and FasL did lead to a significant decrease in PCNA
expression (Figure 9). Since p21/Waf-1 may prevent apop-
tosis by interacting with PCNA [51], we examined the
expression of p21/Waf-1 in dissociated embryonic cortical
cells that were exposed to sFasL, estrogen or both sFasL
and estrogen for 12 hours. Neither estrogen, nor sFasL
alone induced an alteration in p21/Waf1 expression,
though sFasL-treated cultures exhibited a non-statistically
significant trend towards decreased p21/waf-1 expression.
However, the concurrent administration of estrogen and
sFasL led to a significant decrease in the expression of
p21/Waf-1 (Figure 9).
Cyclin-A prevents apoptosis by disrupting the formation
of a complex between the E2F1 and p53 transcription
factors [50]. Therefore, we examined the expression of cyc-
lin-A following exposure to E2 and/or FasL. Both estrogen
and sFasL alone led to a statistically significant increase in
the expression of cyclin-A compared with controls at 12
hours post-treatment. Concurrent exposure to sFasL and
estrogen was not different from exposure to either agent
alone (Figure 9).
Estrogen promotes cell cycle in adherent primary cortical precursors: Figure 6
Estrogen promotes cell cycle in adherent primary cortical precursors: (A) Sample frequency (y-axis) distributions of PI intensity 
(x-axis) along with the best-fit distributions of cells in apoptosis, G0/G1, S-phase or G2/M. The area under the curve delineated 
by diagonal lines (S-phase) is greater in estrogen (E2)-treated cultures compared to controls. (B-E) Quantitative analysis of con-
trol and E2 treated cultures showing the mean % of cells ± SEM in G0 (B), S-phase (C), G2/M (D) or apoptosis (E). Asterisks 
indicate statistical significance at p < 0.05.
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Estrogen and Fas regulation of other cell cycle-related 
proteins
Neither estradiol-17β nor sFasL alone or together altered
the expression of cdk2 or cyclin E compared to control
cultures (Figure 9). Similarly, neither estrogen nor sFasL
significantly altered the expression of Cyclin-dependent
Kinase-1 (cdk1/cdc2) relative to control cultures, suggest-
ing that that interactions between estrogen and Fas activa-
tion were not specifically related to cell cycle.
Discussion
The perinatal cerebral growth spurt is maintained by sev-
eral competing biological processes including neurogene-
sis, neuronal migration, differentiation and cell death,
and hence, represents a critical period of vulnerability to
signals that disrupt cortical development. Cues that alter
the expression of suicide receptors like Fas/Apo-1 are
likely to elicit profound and enduring alterations in the
organization of the developing brain. Our previous data
indicate that Fas-mediated, caspase-dependent death
mechanisms are present during this critical period of cor-
tical development [9]. We therefore set out to ask the
following two questions: (1) 'what developmentally rele-
vant cell biological processes predict cell-surface expres-
sion of Fas?' and (2): 'what are the consequences of Fas
activation for some of these processes?' The data reported
here indicate that there are at least two subpopulations of
cortical neuronal precursors that express Fas receptors, a
small population that expresses extremely high levels of
receptor on their cell surface (the FasHi group) and the
majority of Fas-expressing cells that express moderate lev-
els of Fas on their cell surface (the FasMod group). Since
ventricular-zone cortical neuroblasts also express the Fas
ligand [9], FasHi neuronal precursors may be particularly
sensitive to local suicide signals, and it is not surprising
that, at any given time, a majority of cells in the FasHi
group are apoptotic. In culture, the FasHi  and FasMod
groups together account for approximately one third of all
cells.
Estrogen suppresses Fas expression in adherent primary cortical precursors: Figure 7
Estrogen suppresses Fas expression in adherent primary cortical precursors: (A) Sample flow cytometric scatter plots from 
two control and two E2 treated cultures, showing Fas intensity (y-axis) plotted against cell-cycle stage (PI intensity, x-axis). 
Scatter plots depict a general suppression in cell surface Fas intensity in E2 treated cultures compared to controls. (B,C,E) 
Quantitative analysis (mean ± SEM) of the number of cells expressing Fas (FasMod + FasHi) in control and E2 treated cultures, 
normalized to controls. Since these analyses were performed on adherent cells, the FasHi population was insignificant. (D) 
Quantitative analysis of the mean cell-surface intensity of Fas expression in control and E2 treated cultures. Asterisks indicate 
statistical significance at p < 0.05.
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An analysis of our data shows that a majority (though not
all) of Fas-expressing precursors express the adapter pro-
tein FADD, which enables the activation of caspase-8-
dependent death [42,43]. Presumably, the non-FADD
expressing neuroblasts (~27% of Fas-expressing cells)
couple Fas to other death mechanisms, such as RIP [9] or
DAXX [54]. Furthermore, only a small proportion of Fas-
expressing cells also express the protein FLIP that is capa-
ble of blocking Fas activation [45]. We do not as yet know
whether FLIP expression defines a phenotypically distinct
sub-population of neural precursors. However, it is likely
that this subpopulation is at least functionally distinct,
since neural precursors that are resistant to suicide
receptor-induced death may contribute disproportion-
ately to the overall number of neurons in the cortical
plate.
Our data indicate that cell-surface Fas/Apo-1 expression is
responsive to stage of cell cycle. Though a majority of Fas-
Mod precursors were in G0, cortical cells express higher lev-
els of Fas (determined by immunofluorescence intensity)
in cell cycle, than in G0. Concurrent-analysis of BrdU
incorporation indicates that Fas-expression is particularly
high in cells that have recently completed S-phase or their
final round of mitosis. One possible interpretation of
these data is that Fas expression, and consequently, vul-
nerability to Fas-induced cell death, is tied to cell cycle
checkpoints. Thus, the Fas-suicide system may play a reg-
ulatory role in eliminating cortical progenitor cells that
exhibit signs of genomic instability, cell senescence, errors
in chromosome replication, or DNA damage. Our obser-
vation of a positive relationship between the activation of
p53 (p53 phosphorylation) and Fas expression is particu-
larly germane to the issue of cell cycle control, since p53
regulates progression through cell-cycle checkpoints
[55,56]. Presumably, a p53-associated increase in cell-sur-
face Fas expression would allow 'sentinel' Fas-ligand
expressing cells in the local ventricular zone environment
to eliminate damaged neuroblasts from the pool of pro-
genitors, thereby limiting the likelihood that aberrant
neurons will be added to the cortical plate.
An interesting phenomenon related to our observation
that cell-surface Fas expression is highest at the end of S-
phase, is the association between cell cycle and oscilla-
tory, interkinetic movements of progenitor cells within
the ventricular zone (see Figure 10, ventricular zone
model). As progenitor cells transition from S-phase to
mitosis, their nuclei migrate from the outer margin of the
neuroepithelium to the ventricular surface [57]. Our data
suggest that during this ventricular-fugal nuclear
migration (post-S-phase), cortical progenitors would
exhibit the highest sensitivity to Fas-induced apoptosis.
This scenario is likely to be biologically important,
because genetic defects in proteins such as lissencephaly-
1 (LIS1) that control interkinetic nuclear movements, lead
to enhanced cell death of ventricular-zone neuroblasts
[58]. LIS1 regulates interkinetic movements by interacting
with the microtubule-dynein motor system (reviewed in
[59]). Interestingly, de-polymerization of microtubules
protects hepatocytes from Fas-induced apoptosis [60].
Together, these data suggest a hypothesis that Fas expres-
sion and consequently, suicide-sensitivity, is linked to the
interkinetic movements that accompany cell cycle in the
cortical neuroepithelium.
Motility is also an important feature of the post-mitotic
cortical neuroblast. Differentiating cortical neuroblasts
exit the ventricular zone and populate the cortical plate in
an inside-out gradient, with the younger neuroblasts pop-
ulating successively superficial laminae [61]. Migration
into the cortical plate is mediated by the interactions of
receptors like the integrins with the extracellular matrix
(reviewed in [59]). Our initial observation was that non-
adherent neural cells predominantly segregated to the
FasHi category of cell-surface Fas-expressing cells. There-
fore, in a subsequent experiment, we manipulated the
interactions of neural cells with the extra-cellular matrix.
Densitometric analyses of western immunoblots of samples  obtained from conditionally immortalized CHB50 cortical  neuroblasts cultured for 24 or 72 hours following p53 induc- tion (-tsTA/+pp53 condition) Figure 8
Densitometric analyses of western immunoblots of samples 
obtained from conditionally immortalized CHB50 cortical 
neuroblasts cultured for 24 or 72 hours following p53 induc-
tion (-tsTA/+pp53 condition). During this duration, cultures 
were maintained either under control conditions or were 
exposed to E2 alone or E2 with tamoxifen. E2 induced a sig-
nificant decrease in Fas that was not reversed by concurrent 
exposure to tamoxifen. Asterisks indicate statistical signifi-
cance at p < 0.05.
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Estrogen (E2) and sFasL cooperate to regulate cell-cycle proteins Figure 9
Estrogen (E2) and sFasL cooperate to regulate cell-cycle proteins. Densitometric analyses of western immunoblots of primary 
embryonic precursors treated with sFasL or E2 alone or sFasL concurrently with E2. Concurrent exposure sFasL and E2 sup-
press PCNA (A) and p21/Waf-1 (B) expression at 12 hours. sFasL and E2 separately and together induce cyclin-A (C). sFasL 
and E2 either alone or together do not regulate the expression of cyclin-E, CDK1/CDC2 or CDK2 (D). (E) Sample western 
immunoblots showing regulation of the expression of cell-cycle proteins following treatment with sFasL or E2 alone or 
together. p21Waf-1, cyclin-E and CDK-2 images were each cropped from one single immunoblot to eliminate non-relevant 
treatment conditions. Asterisks indicate statistical significance at p < 0.05.
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Since type-1 collagen engages integrins, we used Colla-
genase-A to disrupt neuroblast interactions with the extra-
cellular collagen matrix. Our results showed that loss of
contact with the collagen matrix resulted in a significant
increase in Fas expression, and was associated with the
phenomenon of 'anoikis'. These data are consistent with a
recent report showing that integrin-mediated T-lym-
phocyte adhesion to extracellular matrix resulted in the
suppression of Fas expression [62]. Anoikis may be rele-
vant to brain development as well, since suppression of
matrix reorganization by deletion of the MMP-9 gene,
leads to delayed migration of cerebellar granule cells and
Models of Fas-mediated suicide sensitivity of precursors during cell cycle, and following disruption of cell-matrix interactions Figure 10
Models of Fas-mediated suicide sensitivity of precursors during cell cycle, and following disruption of cell-matrix interactions. 
Ventricular zone (VZ), interkinetic nuclear movement model: Our data shows that during cell cycle, cell-surface Fas expression is 
highest in neuroblasts that also exhibit the highest level of BrdU incorporation. Such a relationship would occur at the end of 
S-phase, perhaps reflecting DNA replication errors. Therefore, Fas expression (indicated in the cartoon by a green peri-cellular 
halo), and hence suicide-sensitivity would be highest during the ventricular-fugal interkinetic movement of nuclei transitioning 
through G2. Resident Fas-ligand expressing cells (indicated by pacman figures) could eliminate defective Fas-expressing neurob-
lasts. Cortical plate (CP), 'anoikis' model: Cortical neuroblasts utilize integrin-mediated signals to migrate along radial glia and into 
the laminae of the cortical plate [98]. Collagenase-A disrupts integrin-collagen interactions, and our data shows that colla-
genase-A leads to increased cell-surface Fas expression. Therefore, the induction of the Fas receptor may underlie the process 
of 'anoikis'. 'Anoikis' in turn, may protect the developing cerebral cortex from migration errors. Abbreviations: V = ventricular 
zone, VZ = ventricular zone, CP = cortical plate.
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decreased apoptosis [47]. Interestingly, in the context of
our data on estrogen suppression of Fas expression,
homozygous estrogen receptor-beta knockout animals
exhibit defects in the organization of radial glia and
increased apoptosis in cortical ventricular zone neurob-
lasts [63]. These data suggest that migration and apoptosis
are contextually linked to each other in vivo. Perhaps, dif-
ferentiating neurons that migrate to inappropriate posi-
tions within the cortical plate are eliminated by receptor-
mediated suicide mechanisms (see Figure 10, cortical
plate model), analogous to the mechanism that is used to
eliminate self-antigen recognizing lymphocytes in the
immune system [12].
The developing brain's hormonal environment has an
important impact on cell fate determination and the hor-
mone estrogen is an important regulator of cell cycle and
cell suicide in cerebral cortical neuroblasts [37]. Both
identified estrogen receptor subtypes, ERα and ERβ, are
ligand-activated transcription factors [64-68]. Nuclear
estrogen receptors and ERα mRNA are transiently
expressed, at high levels in the developing cerebral cortex
during the peak of neurogenesis and apoptosis [69-71].
ERβ is also expressed in the cerebral cortex [68,72,73].
Estrogen has divergent, region-specific actions on the sur-
vival of neural tissues. For example, estrogen metabolites
induce apoptosis in neuroblastoma cells [74], while estro-
gen promotes survival in hypothalamic cell lines [75] and
in the bed nucleus of Stria Terminalis [10]. Estrogen also
inhibits apoptosis in the sexually dimorphic nucleus of
the preoptic area while inducing apoptosis in the anterov-
entral periventricular nucleus of the preoptic area [76].
Furthermore, ERα and ERβ may also have opposing anti-
and pro-apoptotic roles that are perhaps Fas-ligand
dependent, as supported by evidence from hypothalamic
cell lines [77]. In cerebral cortical neuroblasts, we have
previously shown that estrogen promotes activation of the
transcription factor p53, but uncouples p53 from down-
stream cell suicide signals to promote neuronal survival
[37]. We therefore reasoned that estrogen suppresses
apoptosis in the developing cerebral cortex, in part, by
decreasing the cell-surface expression of the Fas receptor.
This hypothesis was verified by our experiments. The
numbers of neuroblasts in G0 expressing the Fas receptor
declined significantly, following exposure to estradiol-
17beta. Though estrogen did not alter the numbers of cells
in cell cycle (S/G2/M) that expressed Fas, estrogen did
lead to a significant decrease in the average intensity of Fas
expression at the cell-surface. The estrogen-mediated
reduction in numbers of Fas-expressing neuroblasts in G0
is open to several interpretations. The most parsimonious
explanation for the data is that estrogen directly decreased
Fas expression. Alternatively, since estrogen also promotes
neuroblast proliferation [37], estrogen could have led to
the expansion of a progenitor pool that did not express
Fas on the cell surface.
We had previously observed that estrogen prevented
apoptosis in T-antigen-synchronized cultures, following
p53 activation (as indicated by p53 phosphorylation at
serine 392, and activation of prototypic p53-responsive
genes like MDM2, p21/Waf-1 and Bax) [37]. In the cur-
rent study on non-synchronized primary cortical neurob-
lasts, we observed a non-statistically significant trend
towards an estrogen-mediated decrease in apoptosis as
reflected by the presence of cells with less than G0 DNA
content. However, when we restricted the analysis to the
Fas population, we found that estrogen induced a
statistically significant decrease in the numbers of Fas-
expressing cells that were apoptotic. Since Fas expression
was positively associated with p53 phosphorylation, it is
likely that estrogen protection against apoptosis is contex-
tual, i.e., dependent on the activation of p53. Thus, fol-
lowing p53 activation in our CHB50 cortical progenitors,
we found that estrogen also led to a significant decrease in
Fas expression. Interestingly, the estrogen receptor antag-
onist, 4-hydroxytamoxifen, did not block estrogen sup-
pression of Fas expression. We previously observed a
similar tamoxifen-independent effect of estrogen on the
regulation of p53 itself [37], suggesting that estrogen may
regulate cell-surface Fas expression by non-classical mech-
anisms including transcriptional activation mediated by
AP-1 [78] or activation of protein kinase pathways
[79,80].
One issue that remains to be addressed is whether estro-
gen suppresses cell-surface Fas expression by acting as a
non-classical transcription repressor, or by suppressing
translocation of Fas from intracellular compartments to
the cell-surface in a manner that is antagonistic to that
observed for p53 [34]. The timeframe of estrogen's actions
is certainly more consistent with transcription repression,
and perhaps, an antagonism of p53-mediated transcrip-
tion. Both the mouse and human Fas genes contain a p53
response element (p53RE) within intron #1 that drives
transcription of the Fas gene [33]. In silico analysis of the
murine Fas gene (GenBank Accession #AF282865) also
indicates a potential estrogen response element (ERE) in
intron#1. This presumptive ERE consists of a perfect pal-
indrome whose halves are separated by an integer multi-
ple of 3 random base-pairs GGTCA(NNN)83TGACC
(where the canonical ERE is GGTCA(NNN)TGACC [81]).
Four additional hemi-palindromic sequences, identical to
half a canonical ERE are dispersed throughout intron#1,
and may also contribute to estrogen repression of Fas.
These possibilities are supported by our previous research
showing that intronic EREs (e.g., in the Brain-derived neu-
rotrophic factor or BDNF gene) are functional and can
contain integer multiples of the canonical triplet base-pairBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/11
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spacer, between two adjacent hemi-palindromes [82].
Furthermore, repressor functions have been ascribed to
estrogen receptors acting at the promoters for IGF-1 and
IGF-1 receptor in aortic smooth muscle cells [83] and spe-
cific residues on ERα recruit co-repressor protein com-
plexes [84]. One hypothesis that remains to be tested, is
that estrogen receptors and p53 may be mutually repres-
sive. While our data indicates that estrogen suppresses the
expression of p53-induced proteins like Bax [37] and Fas,
other data indicates that p53 can suppress estrogen recep-
tor activation [85], by preventing ER-alpha binding to
EREs.
Since estrogen induces neuroblasts to enter S-phase of cell
cycle, while suppressing the cell-surface expression of Fas,
we decided to examine the extent to which estrogen regu-
lates cell cycle proteins concurrent with Fas activation. We
were particularly interested in the regulation of dual-pur-
pose proteins like cyclin-A, p21/waf-1 and PCNA that not
only regulate progression through cell cycle, but also par-
ticipate in DNA repair and blockage of apoptosis. For
example PCNA and p21/waf-1 initiate repair of double-
strand DNA breaks (a hallmark of apoptosis) [51] while
cyclin A prevents apoptosis by disrupting p53 signaling
[50]. Unexpectedly, concurrent exposure to both estrogen
and to sFasL led to a decrease in the expression of both
PCNA and p21/waf1. Since these proteins play antagonis-
tic roles during cell cycle, it is likely that this co-regulation
will have little net effect on cell cycle per se. On the other
hand, it is likely that capacity to repair double stranded
DNA breaks is curtailed. It is unclear at this time why the
coordinate activation of a suicide receptor and a hormone
receptor would decrease both PCNA and p21/waf1,
potentially compromising DNA repair capacity. Perhaps,
once cell suicide is initiated, and caspase-activated
DNAses create double strand breaks, DNA repair would
be an inefficient mechanism to reverse apoptosis. In this
context, the role of estrogen may be to cleanly facilitate
suicide. This hypothesis is consistent with observations
from other laboratories [76,77] that estrogen can induce
apoptosis in specific brain regions. Estrogen's anti-apop-
totic role may be to prevent the initiation of apoptosis in
the first place, by suppressing expression of p53-activated
proteins like Fas (as reported above) and Bax [37] or alter-
natively, antagonizing p53 more directly. The latter
hypothesis is supported by our observation that estrogen
and Fas-ligand both separately and together, significantly
increased Cyclin-A. Cyclin-A is a G1/S-phase cyclin, so it
is not surprising that estrogen would up-regulate this cyc-
lin as a consequence of increasing the number of neurob-
lasts that enter S-phase. However, cyclin-A can also
antagonize p53-dependent apoptosis [50] by preventing
the association between p53 and E2F, and therefore, may
represent the preferred intermediary for estrogen suppres-
sion of apoptosis. Interestingly, cyclin-E, which does not
compete with E2F for binding to p53 [50], was not
induced by estrogen in our experiments. Additionally,
cyclin-A complexes with CDK2 to induce phosphoryla-
tion of ER-alpha on serines 104 and 106, and consequent
transactivation [86]. It is likely therefore, that the induc-
tion of cyclin-A increases activation of associated kinases,
even though CDK2 levels were not altered, leading to
feedback activation of the estrogen receptor, further sup-
pression of Fas expression, and neuro-protection. If cyc-
lin-A represents a means for limiting apoptosis, then the
induction of cyclin A by sFasL, suggests that neuronal pre-
cursors may initiate adaptive anti-apoptotic mechanisms
(aside from FLIP expression), in response to the activation
of a suicide receptor.
Conclusions
Overall, our results indicate that cell-surface Fas expres-
sion identifies two distinct sub-populations of cortical
neuroblasts, the FasHi and FasMod populations, with FLIP
co-expressing cells comprising perhaps a third popula-
tion. Developmentally, cell-surface Fas expression is mod-
ulated by a variety of competing factors including cell-
cycle stage, extracellular matrix interactions, p53 phos-
phorylation and hormone availability. Dynamic changes
in suicide Fas-mediated sensitivity during development
are likely to play a significant role in the genesis of a vari-
ety of developmental neurodegenerative diseases includ-
ing the Fetal Alcohol Syndrome [87], neonatal cerebral
ischemia [15], neonatal posthemorrhagic hydrocephalus
[88], neonatal brain trauma [89], and genetic diseases
resulting from the expansion of polyglutamine repeats
[16].
Methods
Animals
Timed-pregnant rats (Sprague Dawley) were purchased
from Harlan (TX). Gestational Day (GD) zero was defined
as the day on which dams were sperm positive. GD-15 rat
fetuses were obtained under aseptic conditions, from
pregnant dams that were anesthetized with Phenobarbital
(50 mg). Fetal brains were dissected out aseptically and, in
all cases, care was taken to minimize any pain and dis-
comfort to the animals.
Dissociated primary embryonic cortical cultures
The cerebral cortical mantle of GD-15 rat fetuses was dis-
sected out under sterile conditions, and separated from
overlying meningeal tissue under a microscope. We
selected GD15 because this age represents the peak period
for proliferation within the cortical neuroepithelium, to
generate neurons of the cortical plate. At GD15, the neu-
roepithelium is the dominant cortical structure, though a
smaller number of differentiated neurons (the cortical
preplate) and radial glia are also present. Furthermore, at
this age, the neuroepithelium is mainly comprised ofBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/11
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proliferating neuronal (rather than glial) precursors (for
review see [40]). The earliest developing layer of the corti-
cal plate (layer VI) does not form until one day later
(GD16-17). Morphologically, these cortical cultures are
immature and continue to proliferate in vitro, but over a
period of 24 hours, cultured neuroblasts become increas-
ingly polarized and exhibit growth cones and process
characteristic of early differentiating neurons. Cultures
were established according to our previously published
protocols [9]. Briefly, neuroblasts were dispersed by tritu-
ration in 0.5% trypsin and 6.84 mM EDTA (Sigma) and
were plated on collagen-coated 24-well plates in sterile
culture medium (89% Dulbecco's modified eagle media
[DMEM], 10% gelding serum and 1% penicillin-strepto-
mycin). Cultures were maintained at 37°C for 24 hours
and the culture medium was replaced. For initial experi-
ments, whole cultures were assayed 24 hours later by
FACS (Fluorescence-assisted cell sorting) analysis. For
subsequent experiments, only adherent cells were har-
vested at 24 hours and fixed for FACS analysis. For some
experiments, soluble protein was extracted for western
immunoblot analysis. Some experimental groups were
exposed to soluble Fas Ligand (sFasL 5 ng/ml, Alexis
Corp.), estradiol-17β (2 nM, Sigma) or sFasL together
with estradiol-17β. Control and sFasL-treated cultures
were maintained at 37°C in normal culture medium for
24 hours and then exposed to the appropriate treatments.
Estrogen-treated cultures were pre-treated with estradiol-
17β for 24 hours and then re-fed with estrogen alone or
estrogen concurrently with sFasL for 12 hours.
Immortalized cerebral cortical culture model
To examine the regulation of Fas by p53 and estrogen, we
also utilized a rodent cerebral cortical cell line (CHB50)
conditionally immortalized with a temperature sensitive
mutation of the SV40 large T antigen (tsTA) that we had
previously developed and characterized [37]. In the +tsTA
condition (incubation at 33°C), neuroblasts proliferate
indefinitely and p53 is inactive. However, cessation of
large T antigen expression (-tsTA, 39°C) is accompanied
by induction of the p53 phosphorylation and the induc-
tion of p53-dependent proteins, p21/Waf1, Bax and
MDM2 that lead to cell cycle-arrest, suicide, and p53 inhi-
bition/cell cycle re-entry respectively. We had previously
observed that CHB50 neuroblasts express the estrogen
receptor ER-α and are estrogen-responsive. Estrogen pre-
vents apoptosis following p53 activation and induces
both neurogenesis and neuronal differentiation in this
cell line. CHB50 cortical neuroblasts were therefore cul-
tured under the +tsTA and -tsTA conditions as published
previously [37] to examine the p53-related expression of
Fas, and under the -tsTA conditions to examine the estro-
gen regulation of Fas during neuroblast differentiation (in
the context of p53 activation).
Flow cytometric analysis
Triple parameter flow cytometric analysis was used to
measure immunolabeled cell surface Fas protein, BrdU
incorporation (a measure of DNA incorporation) and
DNA content [propidium iodide (PI) dye intercalation] as
a measure of cell cycle distribution. Dissociated embry-
onic cortical cultures were administered a single BrdU
pulse (24 hours) at the time the cultures were established.
Non-adherent and adherent [harvested by administration
of collagenase (Sigma, 30 units)] cells were obtained after
the initial 24-hour BrdU pulse and centrifuged at 300 × g
to sediment the cells. The pellet was washed with Dul-
becco's Phosphate buffered saline (PBS) and fixed in 1%
paraformaldehyde and re-suspended in PBS. Cells were
sedimented by centrifugation between subsequent immu-
nohistochemical steps. To detect cell-surface Fas/Apo-1,
immuno-histofluorescence chemistry was performed in
the absence of detergent. Following exposure to a block-
ing solution (in Tris-buffered saline, (TBS) pH 7.4, with
0.1%Bovine Serum Albumin, and 2% Normal Goat
Serum), cell-surface Fas/Apo-1 expression was detected
with a rabbit polyclonal anti-Fas antibody (Santa Cruz,
1:500), followed by biotinylated, secondary donkey anti-
rabbit (Jackson Immunochemicals, 1:1000) conjugated to
streptavidin-FITC. Following Fas/Apo-1
immunofluorescence, cells were permeabilized with
detergent (0.3% Trition-X100) in blocking solution. BrdU
incorporation was detected with a primary anti-BrdU anti-
body (Sigma, 1:500) followed by biotinylated, secondary
horse anti-mouse (Vector, 1:1000), conjugated to strepta-
vidin-allophycocyanin (APC, Molecular Probes, 1:500).
The cells were then washed with PBS and exposed to a PI
solution (see above) for 10 minutes at room temperature.
BrdU-allophycocyanin, Fas-FITC and PI fluorescence was
analyzed from 104 cells with excitation at 488 nm (argon
laser) and detection of FITC fluorescence at approximately
530 nm, PI fluorescence at 585 nm and allophycocyanin
at 650 nm.
In studies examining the relationship between cell surface
Fas and Fas-associated protein expression, binding of the
primary antibody, mouse monoclonal antibody to Fas
(Transduction Laboratories, 1:500), was detected using a
rat-absorbed, biotinylated horse-anti-mouse secondary
antibody (Vector, 1:1000), conjugated to streptavidin-
APC or rabbit polyclonal anti-Fas antibody (Santa Cruz,
1:500), followed by biotinylated, secondary donkey anti-
rabbit (Jackson Immunochemicals, 1:1000) conjugated to
streptavidin-FITC. Subsequently, FLIP or phosphorylated
P53 was detected using rabbit polyclonal anti-FLIP (gift
from Drs. Sato and Walsh, Tufts University School of
Medicine; 1:500) or phospho-p53 at serine 392 (New
England BioLabs, 1:500) followed by a secondary donkey
anti-rabbit (Jackson Immunochemicals, 1:1000) conju-
gated to streptavidin-FITC. FADD was detected using aBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/11
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monoclonal anti-FADD antibody (Transduction Labora-
tories, 1:500) followed by a rat-absorbed, biotinylated
horse-anti-mouse secondary antibody (Vector, 1:1000).
Phosphorylation of the casein kinase II-sensitive site at
serine 392 was used as a marker for activated p53. Phos-
phorylation at this site promotes tetramerization of p53
[90] and specificity of p53 binding to DNA [91], while
regulating re-annealing of double-stranded DNA [92].
Cells were then washed with PBS and exposed to a PI solu-
tion [PBS, 0.1% triton (Sigma), 0.5 mmol EDTA, 0.05 mg/
ml RNAse A and 50 mg/ml PI] for 10 minutes at room
temperature. Fas-FITC and PI fluorescence was analyzed
from 10,000 cells using a flow cytometer (Becton Dickin-
son) with excitation at 488 nm (argon laser) and detec-
tion of FITC fluorescence at approximately 530 nm and PI
fluorescence at 585 nm. The specificity of all antibodies
used for flow cytometric analysis was previously verified
by western immunoblot analysis and/or immunohisto-
chemical analysis [9,37]. Immunological controls were
exposed to pre-immune serum in place of the appropriate
primary antibody and were used to determine back-
ground immunofluorescence.
Western immunoblot analysis
The expression of cell cycle elements that regulate S-phase
[proliferating cell nuclear antigen (PCNA)], the G1/S tran-
sition [cyclin dependent kinase 2 (cdk2) and cyclin E], the
G2/M transition [cyclin dependent kinase (cdk1) and cyc-
lin A], and a cell cycle arrest factor [p21/wild-type p53-
activated fragment (Waf1)/Cip1 (cdk-interacting protein-
1)], and Fas were verified by western immunoblot analy-
sis of E15 cortical neuroblasts, according to our previously
published protocols [9,37,93,94]. Detergent (1% SDS)
soluble protein was isolated using the Trizol reagent (Inv-
itrogen). Protein samples were size fractionated on an 8%
SDS-polyacrylamide gel, and blotted onto supported
nitrocellulose (Hibond-C-super, Amersham). Blots were
blocked (5% milk, TBS (1.4 M NaCl, 0.2 M Tris)-0.1%
Tween 20), exposed to primary antibody [mouse
monoclonal anti-PCNA antibody (Calbiochem, 1:66);
rabbit polyclonal anti-cyclin E (Calbiochem, 1:250);
mouse monoclonal anti-cyclin A (Calbiochem, 1:100),
mouse monoclonal anti-cdk2 (Transduction Laborato-
ries, 1:500), mouse monoclonal anti-cdk1 (Calbiochem,
1:100) or mouse monoclonal anti-Fas (Transduction
Labs)], washed and exposed to horse-anti-mouse second-
ary antibody (Vector, 1:1000) or donkey anti-rabbit (Jack-
son Laboratories, 1:5000), washed again and exposed to
streptavidin horseradish-peroxidase conjugate (Amer-
sham). Immunoreactive bands were detected using
enzyme-linked chemiluminescense (NEN).
Data analysis
Data analyses for the experiments reported here were
based on 5–9 independent samples. For FACS analysis,
the incorporation of PI into cellular DNA was used to cat-
egorize cells in G0/G1 (diploid DNA content), S/G2/M
(hyper-diploid DNA content) and apoptosis (sub-diploid
DNA content) [95-97]. Cells were categorized, and inten-
sities calculated using standard cell sorting software (Cell
Quest, Becton Dickinson). Western immunoblots were
analyzed using standard densitometric software (Molecu-
lar Analyst, Bio-Rad). Sample size for western blot analy-
ses was 6. Statistical differences were calculated using
ANOVAs followed by post-hoc tests (Student-Newman-
Keuls, p < 0.05). Correlational analyses were calculated by
combining mean intensity values from 6–8 replications
using Pearson's product moment correlation (r) followed
by a two-tailed test for the significance of the correlation
coefficient. Levels of statistical significance were set at p <
0.05. Data were expressed in terms of mean ± standard
error of the mean (SEM).
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FADD = Fas-associated death domain containing protein
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p21/Waf1 = Wild-type p53-activated fragment 1 or cyclin-
dependent kinase inhibitor 1A
p53RE = p53 response element
PCNA = Proliferating cell nuclear antigen
PI = Propidium iodide
pp53 = Phosphorylated p53 (on serine 392)
SEM = Standard error of the mean
sFasL = soluble Fas-ligand
tsTA = temperature-sensitive SV40 T antigen
V = Ventricle
VZ = Ventricular Zone
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